Cover Image
市場調查報告書

冠狀動脈繞道手術:醫療設備的開發平台評估

Coronary Artery Bypass Graft Surgery - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 357845
出版日期 內容資訊 英文 150 Pages
訂單完成後即時交付
價格
Back to Top
冠狀動脈繞道手術:醫療設備的開發平台評估 Coronary Artery Bypass Graft Surgery - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年09月01日 內容資訊: 英文 150 Pages
簡介

本報告提供冠狀動脈繞道手術相關之開發中產品調查,提供您各開發階段趨勢和產品的主要開發企業,現在進行中的臨床實驗,產業的近幾年趨勢等資訊。

第1章 目錄

第2章 簡介

  • 冠狀動脈繞道手術概要

第3章 開發中的產品

  • 冠狀動脈繞道手術 - 開發中產品:各開發階段
  • 冠狀動脈繞道手術 - 開發中產品:各市場區隔
  • 冠狀動脈繞道手術 - 開發中產品:各地區 (國家)
  • 冠狀動脈繞道手術 - 開發中產品:各法規途徑
  • 冠狀動脈繞道手術 - 開發中產品:各核准時期 (估計)
  • 冠狀動脈繞道手術 - 持續中臨床實驗

第4章 冠狀動脈繞道手術 - 正在開發的開發中產品:各企業

  • 冠狀動脈繞道手術企業 - 開發中產品:各開發階段
  • 冠狀動脈繞道手術 - 開發中產品:各開發階段

第5章 冠狀動脈繞道手術 開發企業與產品概要

  • AdvanSource Biomaterials Corporation
  • Axcelon Biopolymers Corp.
  • CardioPolymers, Inc.
  • CellProthera
  • Coromedic Ltd.
  • Cytograft Tissue Engineering, Inc.
  • Elana bv
  • Endogene Ltd
  • Graft-Loc Inc.
  • H. Lee Moffitt Cancer Center & Research Institute, Inc.
  • iiTech BV
  • Magenta Medical Inc
  • Miracor Medical Systems GmbH
  • Neograft Technologies, Inc.
  • NuVascular Technologies Inc
  • Prekubator TTO
  • Revivicor, Inc.
  • SeamVad Ltd.
  • St. Jude Medical, Inc.
  • Tengion, Inc.
  • The University of Utah
  • Tissue Regeneration Technologies, LLC
  • University College London
  • University of Arizona
  • University of California, Los Angeles

第6章 冠狀動脈繞道手術 - 近幾年趨勢

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0423EPD

GlobalData's Medical Devices sector report, "Coronary Artery Bypass Graft Surgery - Medical Devices Pipeline Assessment, 2017" provides an overview of Coronary Artery Bypass Graft Surgery currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Coronary Artery Bypass Graft Surgery pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Coronary Artery Bypass Graft Surgery under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Coronary Artery Bypass Graft Surgery and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Coronary Artery Bypass Graft Surgery under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Introduction 8

  • 2.1 Coronary Artery Bypass Graft Surgery Overview 8

3 Products under Development 9

  • 3.1 Coronary Artery Bypass Graft Surgery - Pipeline Products by Stage of Development 9
  • 3.2 Coronary Artery Bypass Graft Surgery - Pipeline Products by Segment 10
  • 3.3 Coronary Artery Bypass Graft Surgery - Pipeline Products by Territory 11
  • 3.4 Coronary Artery Bypass Graft Surgery - Pipeline Products by Regulatory Path 12
  • 3.5 Coronary Artery Bypass Graft Surgery - Pipeline Products by Estimated Approval Date 13
  • 3.6 Coronary Artery Bypass Graft Surgery - Ongoing Clinical Trials 14

4 Coronary Artery Bypass Graft Surgery - Pipeline Products under Development by Companies 15

  • 4.1 Coronary Artery Bypass Graft Surgery Companies - Pipeline Products by Stage of Development 15
  • 4.2 Coronary Artery Bypass Graft Surgery - Pipeline Products by Stage of Development 17

5 Coronary Artery Bypass Graft Surgery Companies and Product Overview 18

  • 5.1 AdvanSource Biomaterials Corporation Company Overview 18
    • 5.1.1 AdvanSource Biomaterials Corporation Pipeline Products & Ongoing Clinical Trials Overview 18
  • 5.2 Axcelon Biopolymers Corp. Company Overview 19
    • 5.2.1 Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.3 CardioPolymers Inc Company Overview 20
    • 5.3.1 CardioPolymers Inc Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.4 Cardious, Inc. Company Overview 21
    • 5.4.1 Cardious, Inc. Pipeline Products & Ongoing Clinical Trials Overview 21
  • 5.5 CellProthera Company Overview 22
    • 5.5.1 CellProthera Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.6 Coromedic Ltd. Company Overview 25
    • 5.6.1 Coromedic Ltd. Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.7 Cytograft Tissue Engineering Inc (Inactive) Company Overview 27
    • 5.7.1 Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.8 Elana bv Company Overview 28
    • 5.8.1 Elana bv Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.9 Endogene Ltd Company Overview 30
    • 5.9.1 Endogene Ltd Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.10 Graft-Loc Inc. Company Overview 31
    • 5.10.1 Graft-Loc Inc. Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.11 H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview 32
    • 5.11.1 H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.12 Humacyte Inc Company Overview 33
    • 5.12.1 Humacyte Inc Pipeline Products & Ongoing Clinical Trials Overview 33
  • 5.13 iiTech BV Company Overview 34
    • 5.13.1 iiTech BV Pipeline Products & Ongoing Clinical Trials Overview 34
  • 5.14 LeMaitre Vascular Inc Company Overview 36
    • 5.14.1 LeMaitre Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.15 Magenta Medical Inc Company Overview 37
    • 5.15.1 Magenta Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.16 McGill University Company Overview 38
    • 5.16.1 McGill University Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.17 Miracor Medical Systems GmbH Company Overview 39
    • 5.17.1 Miracor Medical Systems GmbH Pipeline Products & Ongoing Clinical Trials Overview 39
  • 5.18 Neograft Technologies Inc Company Overview 42
    • 5.18.1 Neograft Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.19 Nice University Hospital Company Overview 45
    • 5.19.1 Nice University Hospital Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.20 NuVascular Technologies Inc Company Overview 46
    • 5.20.1 NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 46
  • 5.21 Palmaz Scientific Inc (Inactive) Company Overview 47
    • 5.21.1 Palmaz Scientific Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 47
  • 5.22 PetVivo Holdings Inc Company Overview 48
    • 5.22.1 PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 48
  • 5.23 Prekubator TTO Company Overview 49
    • 5.23.1 Prekubator TTO Pipeline Products & Ongoing Clinical Trials Overview 49
  • 5.24 RegenMedTX LLC Company Overview 50
    • 5.24.1 RegenMedTX LLC Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.25 Revivicor Inc Company Overview 51
    • 5.25.1 Revivicor Inc Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.26 Rox Medical Inc Company Overview 52
    • 5.26.1 Rox Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.27 SeamVad Ltd. Company Overview 53
    • 5.27.1 SeamVad Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53
  • 5.28 The University of Utah Company Overview 54
    • 5.28.1 The University of Utah Pipeline Products & Ongoing Clinical Trials Overview 54
  • 5.29 Thoratec Corp Company Overview 55
    • 5.29.1 Thoratec Corp Pipeline Products & Ongoing Clinical Trials Overview 55
  • 5.30 Tissue Regeneration Technologies LLC Company Overview 56
    • 5.30.1 Tissue Regeneration Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 56
  • 5.31 University College London Company Overview 57
    • 5.31.1 University College London Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.32 University of Arizona Company Overview 58
    • 5.32.1 University of Arizona Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.33 University of California Los Angeles Company Overview 59
    • 5.33.1 University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 59

6 Coronary Artery Bypass Graft Surgery- Recent Developments 60

  • 6.1 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 60

6.2 Aug 09, 2017: U.S. Stem Cell Reports Most Successful Financial Performance in the Company's History 62

  • 6.3 Aug 08, 2017: Dextera Surgical Reports Fiscal 2017 Fourth Quarter Financial Results 63
  • 6.4 Aug 02, 2017: Cardiovascular Systems Reports Fiscal 2017 Fourth-Quarter Financial Results 64
  • 6.5 Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 66
  • 6.6 Jul 27, 2017: LeMaitre Q2 2017 Record Sales $25.8 mm (+15%), Record EPS $0.23 (+69%) 73
  • 6.7 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 73
  • 6.8 Jul 27, 2017: AtriCure Reports Second Quarter 2017 Financial Results 75
  • 6.9 Jul 18, 2017: AtriCure Announces Hiring of Chief Technology Officer 76
  • 6.10 Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 77
  • 6.11 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 78
  • 6.12 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 80
  • 6.13 May 24, 2017: Fortimedix Surgical Strengthens U.S. Commercial Team with Appointment of David Castiglioni as Vice President of Sales in the United States 83
  • 6.14 May 10, 2017: The Centers for Disease Control and Prevention Updated Guideline Now Include a Recommendation for Triclosan-Coated Sutures 84
  • 6.15 May 04, 2017: AtriCure Reports First Quarter 2017 Financial Results 84
  • 6.16 May 04, 2017: Dextera Surgical Reports Fiscal 2017 Third Quarter Financial Results 85
  • 6.17 May 03, 2017: Cardiovascular Systems Reports Fiscal 2017 Third-Quarter Financial Results 87
  • 6.18 Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results 88
  • 6.19 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 95
  • 6.20 Apr 26, 2017: LeMaitre Q1 2017 Record Sales $24.1 mm (+19%), Net Income $3.2 mm (+49%) 96
  • 6.21 Apr 24, 2017: Dextera Surgical Announces Preliminary Fiscal 2017 Third Quarter Financial Highlights 97
  • 6.22 Apr 12, 2017: Sanofi appoints Nikhilesh Kalra to lead Consumer Healthcare business for India and South Asia 97
  • 6.23 Apr 11, 2017: Sanofi Announces Pre-quarterly Results Communication 97
  • 6.24 Apr 05, 2017: Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee 99
  • 6.25 Mar 06, 2017: AtriCure Announces hiring of Senior Vice President of Clinical, Regulatory, and Scientific Affairs 99
  • 6.26 Mar 02, 2017: Sanofi's Board of Directors Proposes Appointment of Melanie Lee, PhD and Bernard Charles as New Independent Directors 100
  • 6.27 Feb 28, 2017: AtriCure Reports Fourth Quarter and Full Year 2016 Financial Results 101
  • 6.28 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 102
  • 6.29 Feb 21, 2017: Cardiovascular Systems Announces Healthcare Veteran Martha Goldberg Aronson Joins Board of Directors 105
  • 6.30 Feb 21, 2017: LeMaitre Q4 2016 Record Sales $23.3 mm (+14%), Op. Income $3.9 mm (+27%) 105
  • 6.31 Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER 106
  • 6.32 Feb 07, 2017: Dextera Surgical Reports Fiscal 2017 Second Quarter Financial Results 114
  • 6.33 Feb 06, 2017: Maquet Expands Patent Infringement Lawsuit Against Saphena Medical and Dr. Chin, Adds Claims for False Advertising and Correction of Patent Inventorship 116
  • 6.34 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 116
  • 6.35 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 117
  • 6.36 Feb 01, 2017: Sanofi Appoints Hugo Fry as General Manager UK 118
  • 6.37 Jan 30, 2017: Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice President, External Affairs 119
  • 6.38 Jan 25, 2017: Cardiovascular Systems Reports Fiscal 2017 Second-Quarter Financial Results 119
  • 6.39 Jan 09, 2017: AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2016 121
  • 6.40 Dec 19, 2016: Maquet Files Suit against Saphena Medical, Inc. and Dr. Albert Chin to Protect its Intellectual Property 122
  • 6.41 Dec 07, 2016: New governance at CellProthera 123
  • 6.42 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 123
  • 6.43 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 126
  • 6.44 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 127
  • 6.45 Nov 11, 2016: AtriCure Names Sven Wehrwein to its Board of Directors 127
  • 6.46 Nov 07, 2016: Dextera Surgical Reports Fiscal 2017 First Quarter Financial Results 128
  • 6.47 Oct 28, 2016: Sanofi Announces Strong Q3 2016 Results 129
  • 6.48 Oct 27, 2016: AtriCure Reports Third Quarter 2016 Financial Results 136
  • 6.49 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 137
  • 6.50 Oct 26, 2016: Cardiovascular Systems Reports Fiscal 2017 First-Quarter Financial Results 139
  • 6.51 Oct 26, 2016: LeMaitre Q3 2016 Record Sales $23.2 mm (+22%), Record Op. Income $5.3 mm (+61%) 140
  • 6.52 Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results 141
  • 6.53 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 143
  • 6.54 Sep 30, 2016: Sanofi Appoints Alan Main to Executive Committee and Executive Vice President, Consumer Healthcare 143
  • 6.55 Sep 27, 2016: Hannu Syrjala Appointed as New Chairman for Medtentia's Board of Directors 144
  • 6.56 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 144
  • 6.57 Sep 07, 2016: Sanofi Appoints New Research Head for Immunology and Inflammation 145
  • 6.58 Sep 06, 2016: Sanofi Board Of Directors Provides Update 145

7 Appendix 147

  • 7.1 Methodology 147
  • 7.2 About GlobalData 150
  • 7.3 Contact Us 150
  • 7.4 Disclaimer 150

List of Tables

1.1 List of Tables

  • Table 1: Coronary Artery Bypass Graft Surgery - Pipeline Products by Stage of Development 9
  • Table 2: Coronary Artery Bypass Graft Surgery - Pipeline Products by Segment 10
  • Table 3: Coronary Artery Bypass Graft Surgery - Pipeline Products by Territory 11
  • Table 4: Coronary Artery Bypass Graft Surgery - Pipeline Products by Regulatory Path 12
  • Table 5: Coronary Artery Bypass Graft Surgery - Pipeline Products by Estimated Approval Date 13
  • Table 6: Coronary Artery Bypass Graft Surgery - Ongoing Clinical Trials 14
  • Table 7: Coronary Artery Bypass Graft Surgery Companies - Pipeline Products by Stage of Development 15
  • Table 8: Coronary Artery Bypass Graft Surgery - Pipeline Products by Stage of Development 17
  • Table 9: AdvanSource Biomaterials Corporation Pipeline Products & Ongoing Clinical Trials Overview 18
  • Table 10: CardioPass - Product Status 18
  • Table 11: CardioPass - Product Description 18
  • Table 12: Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 19
  • Table 13: BNC - PVA Based Vascular Graft - Product Status 19
  • Table 14: BNC - PVA Based Vascular Graft - Product Description 19
  • Table 15: CardioPolymers Inc Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 16: Plexisyl-AF - Product Status 20
  • Table 17: Plexisyl-AF - Product Description 20
  • Table 18: Cardious, Inc. Pipeline Products & Ongoing Clinical Trials Overview 21
  • Table 19: AvA Aortic Valve Bypass Graft System - Product Status 21
  • Table 20: AvA Aortic Valve Bypass Graft System - Product Description 21
  • Table 21: CellProthera Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 22: StemXpand Automated Device - Product Status 22
  • Table 23: StemXpand Automated Device - Product Description 22
  • Table 24: CellProthera - Ongoing Clinical Trials Overview 23
  • Table 25: StemXpand Automated Device - A Multicentric Controlled Phase I / IIb Study Evaluating the Safety and the Efficacy of in Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand Automated Process, and Injected in Patients with an Acute Myocardial Infarction and a Left Ventricle Ejection Fraction (LVEF) Remaining Below or Equal to 45% after PTCA and Stent(s) Implantation Versus Standard of Care 24
  • Table 26: Coromedic Ltd. Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 27: Distal Anastomosis Device - Product Status 25
  • Table 28: Distal Anastomosis Device - Product Description 25
  • Table 29: Proximal Anastomosis Device - Product Status 26
  • Table 30: Proximal Anastomosis Device - Product Description 26
  • Table 31: Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 32: LifeLine TEBV - CABG - Product Status 27
  • Table 33: LifeLine TEBV - CABG - Product Description 27
  • Table 34: Elana bv Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 35: Artificial Vessel - Product Status 28
  • Table 36: Artificial Vessel - Product Description 28
  • Table 37: ELANA CLIP 3.0 - Product Status 29
  • Table 38: ELANA CLIP 3.0 - Product Description 29
  • Table 39: Endogene Ltd Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 40: Linear Vascular Anastomosis System - Product Status 30
  • Table 41: Linear Vascular Anastomosis System - Product Description 30
  • Table 42: Graft-Loc Inc. Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 43: Graft-Loc Device - Product Status 31
  • Table 44: Graft-Loc Device - Product Description 31
  • Table 45: H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 46: Vascular Stent - Product Status 32
  • Table 47: Vascular Stent - Product Description 32
  • Table 48: Humacyte Inc Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 49: HAV Graft - CABG - Product Status 33
  • Table 50: HAV Graft - CABG - Product Description 33
  • Table 51: iiTech BV Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 52: S² Distal Anastomotic System - Product Status 34
  • Table 53: S² Distal Anastomotic System - Product Description 34
  • Table 54: S² Proximal Anastomotic System - Product Status 35
  • Table 55: S² Proximal Anastomotic System - Product Description 35
  • Table 56: LeMaitre Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 57: Elongated AnastoClip GC - Product Status 36
  • Table 58: Elongated AnastoClip GC - Product Description 36
  • Table 59: Magenta Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 60: Magenta Device - Congestive Heart Failure - Product Status 37
  • Table 61: Magenta Device - Congestive Heart Failure - Product Description 37
  • Table 62: McGill University Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 63: Transcatheter Aorta Pulmonary Shunt - Product Status 38
  • Table 64: Transcatheter Aorta Pulmonary Shunt - Product Description 38
  • Table 65: Miracor Medical Systems GmbH Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 66: PiCSOAMI Impulse Console - CABG - Product Status 39
  • Table 67: PiCSOAMI Impulse Console - CABG - Product Description 39
  • Table 68: Miracor Medical Systems GmbH - Ongoing Clinical Trials Overview 40
  • Table 69: PiCSOAMI Impulse Console - CABG - Pressure Controlled Intermittent Coronary Sinus Occlusion as an Adjunct to PCI in Acute Coronary Syndrome. (An Observational Study Evaluating the Effect of PICSO Treatment Concomitant to pPCI in Patients with Anterior NSTEMI or Following pPCI in STEMI) (An Observational Study Evaluating the Effect of PICSO Treatment Concomitant to PPCI in Patients with Anterior NSTEMI or Following pPCI in STEMI) 41
  • Table 70: Neograft Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 71: Angioshield - Product Status 42
  • Table 72: Angioshield - Product Description 42
  • Table 73: Neograft Technologies Inc - Ongoing Clinical Trials Overview 43
  • Table 74: Angioshield - Feasibility Study to Demonstrate the Safety of the Angioshield System to Provide Mechanical Support for Vein Grafts Used in CABG Surgery: THE ANGIOSHIELD STUDY 44
  • Table 75: Nice University Hospital Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 76: Shark Anastomosis Connector - Product Status 45
  • Table 77: Shark Anastomosis Connector - Product Description 45
  • Table 78: NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 79: BioFunc - APC Vascular Graft - Product Status 46
  • Table 80: BioFunc - APC Vascular Graft - Product Description 46
  • Table 81: Palmaz Scientific Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 82: SESAME Stent - Product Status 47
  • Table 83: SESAME Stent - Product Description 47
  • Table 84: PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 85: Coronary Artery Bypass Graft - Product Status 48
  • Table 86: Coronary Artery Bypass Graft - Product Description 48
  • Table 87: Prekubator TTO Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 88: Snapcon - Product Status 49
  • Table 89: Snapcon - Product Description 49
  • Table 90: RegenMedTX LLC Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 91: Neo-Vessel Replacement - Coronary Artery Bypass - Product Status 50
  • Table 92: Neo-Vessel Replacement - Coronary Artery Bypass - Product Description 50
  • Table 93: Revivicor Inc Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 94: Blood Vessel - Product Status 51
  • Table 95: Blood Vessel - Product Description 51
  • Table 96: Rox Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 97: ROX Anastomotic Coupler System - Product Status 52
  • Table 98: ROX Anastomotic Coupler System - Product Description 52
  • Table 99: SeamVad Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 100: MySide - Product Status 53
  • Table 101: MySide - Product Description 53
  • Table 102: The University of Utah Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 103: Automated Arterial Anastomotic Device - Product Status 54
  • Table 104: Automated Arterial Anastomotic Device - Product Description 54
  • Table 105: Thoratec Corp Pipeline Products & Ongoing Clinical Trials Overview 55
  • Table 106: Automated Anastomosis Device - Product Status 55
  • Table 107: Automated Anastomosis Device - Product Description 55
  • Table 108: Tissue Regeneration Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 109: Cardiogold - Product Status 56
  • Table 110: Cardiogold - Product Description 56
  • Table 111: University College London Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 112: Small Diameter Conduit - Product Status 57
  • Table 113: Small Diameter Conduit - Product Description 57
  • Table 114: University of Arizona Pipeline Products & Ongoing Clinical Trials Overview 58
  • Table 115: Vascular Anastomosis Device - Product Status 58
  • Table 116: Vascular Anastomosis Device - Product Description 58
  • Table 117: University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 118: Sutureless Anastomosis Device - Product Status 59
  • Table 119: Sutureless Anastomosis Device - Product Description 59
  • Table 120: Glossary 149

List of Figures

1.2 List of Figures

  • Figure 1: Coronary Artery Bypass Graft Surgery - Pipeline Products by Stage of Development 9
  • Figure 2: Coronary Artery Bypass Graft Surgery - Pipeline Products by Segment 10
  • Figure 3: Coronary Artery Bypass Graft Surgery - Pipeline Products by Territory 11
  • Figure 4: Coronary Artery Bypass Graft Surgery - Pipeline Products by Regulatory Path 12
  • Figure 5: Coronary Artery Bypass Graft Surgery - Pipeline Products by Estimated Approval Date 13
  • Figure 6: Coronary Artery Bypass Graft Surgery - Ongoing Clinical Trials 14
Back to Top